The chairman of "Borrowing Vests" to buy and sell its own stock Hanson Pharmaceutical was fined 100,000 yuan

On the evening of September 23, Hansen Pharmaceutical (SZ002412, a stock price of 5.3 yuan, a market value of 2.667 billion yuan) issued an announcement.

On July 5th, Liu Zhengqing received the "Notice of File Case" issued by the CSRC issued by the CSRC because of the suspected short -term trading Hansen Pharmaceutical stocks, and the Securities Regulatory Commission decided to file a case. "Daily Economic News" reporter noticed that in October last year, Liu Lingan, the actual controller of Hansen Pharmaceutical, was filed for suspected manipulation of the securities market.

Take the initiative to explain the facts of illegal

According to the announcement, Liu Zhengqing served as the vice chairman and general manager of Hanson Pharmaceutical from May 2014 to May 2020; since May 2020, he has been the chairman and general manager of Hanton Pharmaceutical. The survey situation shows that on January 3, 2014, Liu Zhengqing taught Hu Moumou to open a capital account of 82 ********* 860 under the business department of Shenwan Hongyuan Securities, and hang the Shanghai shareholder account A4 ******* 72 and Shenzhen Certificate shareholders account 01 ******* 59.

From February 5th, 2015 to July 28, 2020, the transfer of silver transfers of the securities account of Hu Moumou was transferred from Liu Zhengqing's own funds and borrowing funds. With borrowing, all profit and loss shall be borne by Liu Zhengqing. From February 27th, 2015 to July 28, 2020, Hu Moumou's securities account trading Hanson Pharmaceutical was jointly operated by Liu Zhengqing and Liu Moumou. Liu Zhengqing entrusted Liu Moumou to watch the securities account. The ordering equipment was mainly Liu Zhengqing's mobile phone, office computer and Liu Moumou's mobile phone.

Combined with account opening, capital exchanges, transaction equipment and inquiry transcripts, the Securities Regulatory Commission Hunan Supervision Bureau believes that Liu Zhengqing is the actual controller of the "Hu Moumou" securities account.

From February 27, 2015 to July 28, 2020, the account has a total of 28 trading days of Hanson Pharmaceutical Stocks, with a cumulative purchase of 672,800 shares, with a transaction value of 11.379 million yuan. 31.9573 million yuan.

During the survey, Liu Zhengqing actively cooperated with the investigation and actively explained the act of illegal facts, and returned the short -term transaction income to Hanson Pharmaceutical to 1.35 million yuan. Therefore, in accordance with relevant laws and regulations, the Hunan Supervision Bureau of the China Securities Regulatory Commission intends to warn it and impose a fine of 100,000 yuan.

Hansen Pharmaceutical said that the subject of the punishment involved in the "Administrative Penalty Promise" is not a listed company and will not affect the daily operations of listed companies. As of now, everything is normal in production and operation, and it will continue to pay attention to the progress of the above matters, and strictly fulfill the information disclosure obligations in accordance with relevant laws and regulations.

Last year, the actual controller was filed by the actual controller

It is worth mentioning that just last year, the actual controller of Hanson Pharmaceutical was filed for suspected manipulation of the securities market.

Hainan Hanson Holdings (Limited Partnership) (hereinafter referred to as Hainan Hanson) is the controlling shareholder of Hansen Pharmaceutical, holding 42.13%of the listed company, Liu Lingan is the actual controller of a listed company.

According to the announcement on October 27, 2021, Hainan Hansen's executive partner and the actual controller of the listed company Liu Lingan received the "Notice of File C case" by the China Securities Regulatory Commission on October 25, 2021. The China Securities Regulatory Commission decided to establish a case against Liu Ling'an in accordance with relevant laws and regulations.

In addition, on August 13, 2021, Hansen Pharmaceutical also announced that he received the "Decision on Administrative Regulatory Measures to Obipulation of Hansen Pharmaceuticals" issued by the China Securities Regulatory Commission Hunan Regulatory Bureau.

Daily Economic News

- END -